FDA Opens a 510(k) Exemption for Federal Drug-Testing Devices

A premarket-notification carve-out that had applied narrowly for years is gone. FDA's 6 October 2026 final order lets clinical toxicology test systems intended for federal drug-testing programs claim the same 510(k) exemption that employment- and insurance-testing devices in the same category have held — a change device makers serving federal drug-testing programs, including the trucking industry's long-stalled push for oral fluid testing, had been waiting on since FDA floated it in May.

The carve-out this order removes

FDA already exempted most Class II clinical toxicology test systems from premarket notification when intended for employment or insurance testing — categories like workplace drug screening panels have operated under that exemption for years. What the exemption did not cover was the same device type intended specifically for use in federal drug-testing programs, which Department of Transportation-regulated and other federal contexts require to follow separate, more stringent protocols. A manufacturer building a toxicology test system for a federal program therefore had to clear 510(k) review even where an otherwise-identical device built for private employment screening would not. The 6 October order removes that distinction, letting federal-program test systems rely on the same exemption as their private-sector counterparts, within the limitations the order sets out.

What the exemption covers

The order applies to 14 categories of clinical toxicology test systems, the panel of substance classes most associated with workplace and federal drug testing: amphetamines, cocaine and cocaine metabolites, methamphetamine, cannabinoids and opiates among them. Exempting a device type from 510(k) does not exempt it from FDA's other device requirements — manufacturers remain subject to the quality system regulation, registration and listing, and the order's own stated limitations on the exemption's scope. For devices used in federal programs specifically, FDA's order also preserves Substance Abuse and Mental Health Services Administration certification requirements, which exist independently of FDA's premarket pathway and are not affected by this change.

A five-month path from proposal to final order

FDA floated the exemption in a 1 May 2026 Federal Register notice of intent, opening a comment period that ran through 30 June. Roughly 70 commenters responded, and trade coverage of the docket describes the majority as supportive of the expanded exemption. FDA finalized the order without modification from the May proposal — a relatively direct path from notice to final action, and one that tracks the agency's broader, device-type-by-device-type approach to expanding premarket exemptions for mature, well-characterized device categories rather than reopening 510(k) review case by case.

Why trucking and oral fluid testing are watching this closely

The clearest practical beneficiary of this order is oral fluid drug testing for DOT-regulated safety-sensitive positions, including commercial drivers — a testing method the industry has pushed for as an alternative to urine testing, partly for collection-site logistics and partly to reduce opportunities for sample adulteration. Removing the 510(k) requirement for federal-program toxicology test systems clears one premarket obstacle for oral fluid device makers. It does not, on its own, make the method usable: DOT's own rule requires at least two oral fluid laboratories to receive HHS certification before DOT-regulated employers may begin oral fluid collections, and that certification process is independent of FDA's device exemption. For regulatory affairs teams at diagnostics companies serving this space, the operative takeaway is that a premarket barrier has come down while a separate, non-FDA certification gate remains open.

Frequently asked questions

What did FDA publish on 6 October 2026?

A final order, "Medical Devices; Exemptions From Premarket Notification: Class II Devices; Certain Clinical Toxicology Test Systems," FR Doc. 2026-20448, docket FDA-2026-N-4268. It removes the exclusion that had kept clinical toxicology test systems intended for federal drug-testing programs outside FDA's existing 510(k) exemption for Class II clinical toxicology test systems, covering 14 device categories including systems for amphetamines, cocaine and its metabolites, methamphetamine, cannabinoids and opiates.

What changes for device makers?

Before this order, a clinical toxicology test system could already be exempt from 510(k) review if intended for employment or insurance testing, but the exemption carved out devices intended for federal drug-testing programs, which still had to go through premarket notification for that use. The final order removes that carve-out, so qualifying test systems intended for federal programs can now rely on the same exemption, subject to the order's limitations and to other applicable FDA requirements.

Does this make DOT oral fluid drug testing operational?

Not by itself. Removing the 510(k) requirement clears a premarket step for the test systems, but Department of Transportation-regulated employers cannot begin using oral fluid testing until at least two oral fluid laboratories receive mandatory certification from the Department of Health and Human Services under its own drug-testing guidelines; devices exempted under this order also remain subject to those guidelines when used in federal programs.

How did FDA reach the final order?

FDA proposed the exemption in a 1 May 2026 Federal Register notice of intent (FR Doc. 2026-08499), with a public comment period that closed 30 June 2026. The agency received comments from approximately 70 commenters, most supporting the expanded exemption, and finalized the proposal without modification five months later.